Antibody Drug Conjugates (ADC) molecules utilize specific antibodies to deliver therapeutic small molecules specifically to cancer cells. ADC are created in cooperation with Bai-Li Pharmaceutical’s R&D Center of Excellence and enable the development of sophisticated chemistries that give this class of drugs their therapeutic payload. This advanced functional class is referred to as Heterogeneity overcoming - Immunogenic death inducing - Resistance antagonizing - Enhanced Specificity (HIRE) molecules that target cancer cells.

The ADC BL-M05D1 is developed using a proprietary claudin 18.2 specific antibody. Due to its claudin 18.2 specific binding, BL-M05D1 has specificity toward claudin 18.2 expressing malignancies including gastric cancer. The BL-M05D1 is engineered to have an IgG wt FC receptor allowing for the mediation of innate immune effector and compliment mediated functions toward the cancer cells. Upon antibody mediated internalization, BL-M05D1 is trafficked to cancer cell lysosomes and liberates its therapeutic payload that induced genotoxic stress activating pathways leading to cancer cell death.

BL-M05D1 is currently being evaluated as a single agent in clinical trials enrolling patients with a variety of claudin18.2 expressing malignancies.